|Bid||24.52 x 1000|
|Ask||25.26 x 800|
|Day's Range||24.94 - 25.56|
|52 Week Range||24.10 - 32.78|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||5.30|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||0.52 (2.10%)|
|1y Target Est||30.40|
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before last year's Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the […]
Corteva, Inc. (NYSE: CTVA) announced Corteva Executive Vice President and Chief Financial Officer, Greg Friedman, will participate in the Citi Basic Materials Conference in New York, NY at 8:45 a.m. Eastern Time, on Wednesday, December 4, 2019.
WILMINGTON, Del., Nov. 7, 2019 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announced Corteva Chief Executive Officer, James C. Collins, Jr. During his presentation, Collins will provide additional granularity on the Company's 2019 performance. Collins will also discuss recent strategic and financial updates along with portfolio and productivity actions that are setting the stage for 2020.
Two companies that supply farmers— (CTVA) and (FMC)—are on different paths as investors assess their quarterly results. The stock (ticker: CTVA) fell 4% Thursday, worse than the 0.5% decline of the Dow Jones Industrial Average. For Corteva, “we had previously thought there was a possibility that domestic corn yields might be significantly impaired in 2019 due to adverse weather conditions that led to a very late planting season,” wrote Zekauskas in a Friday research report.
The third quarter is a seasonally soft patch for agricultural companies. Corteva lost 39 cents a share, but that was better than the 45-cent loss Wall Street expected.
Corteva Inc said on Thursday demand for grains and oilseeds could be hit by a delayed soybean planting in Brazil and cooling growth in China and emerging economies, sending its shares down 8%. Persistent dry weather has pushed out soybean planting and the use of crop protection products in Brazil, the world's top exporter of the oilseed, while purchases by top buyer China have been erratic due to Beijing's trade war with Washington, which has also hit growth at the world's second-largest economy. "Coupled with production disruptions and delays, recent softening in the Chinese economy, African swine fever and slower growth in other emerging markets are impacting the demand outlook for commodity grains and oilseeds," Chief Executive Officer James Collins said on a post earnings call.
Persistent dry weather has pushed out soybean planting and the use of crop protection products in Brazil, the world's top exporter of the oilseed, while purchases by top buyer China have been erratic due to Beijing's trade war with Washington, which has also hit growth at the world's second-largest economy. "Coupled with production disruptions and delays, recent softening in the Chinese economy, African swine fever and slower growth in other emerging markets are impacting the demand outlook for commodity grains and oilseeds," Chief Executive Officer James Collins said on a post earnings call.
WILMINGTON, Del., Oct. 31, 2019 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) today announced its Board of Directors has approved a $145 million capital investment in the Company's Midland, Mich. manufacturing facility to expand global capacity for the Company's high-demand insect management technology for the natural products market. The capacity expansion project was initiated in response to consistently high demand for Corteva's Spinosyns products, including Spinetoram and Spinosad. Staged to come online over the next few years, the new production will enable Corteva to increase its existing Spinosyns capacity by 30% – addressing the needs of customers in the more than 100 countries into which these solutions are sold around the world for use on more than 100 different crops.
-GAAP earnings per share (EPS) from continuing operations was a loss of $(0.69) for the third quarter and operating EPS¹ was a loss of $(0.39) - both improved compared to prior year². -Net sales were $1.9 ...
Corteva's (CTVA) Q3 performance is likely to have been impacted by softness in North American market. However, the company is on track with cost saving initiatives.
Growth investors are constantly looking for the next massive gainer. We mean the stocks that not only have a proven track record for growth but also exhibit strong long-term growth prospects that could yield high rewards in the years to come.While it’s often tempting to turn to more mainstream names like Apple, these better-known stocks don’t always offer the most upside from the current share price. In this case, stocks that have slipped away from investors' radars can represent more compelling investments as their biggest gains could still be on the way.That being said, finding these under-the-radar names that are poised to skyrocket can seem like a daunting task to even the most seasoned investors. Luckily, TipRanks’ Smart Score tool makes it a little easier. Using the tool, we were able to pinpoint 3 lesser-known stocks primed to take off.Teleflex (TFX)Teleflex develops and manufactures single-use medical devices such as products used for anesthesia, fluid management as well as hand-held instruments. While experiencing a rocky last few months, several analysts believe TFX is well positioned to deliver high returns.Part of the medical device company’s appeal lies with its UroLift product. The system, which is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), has been approved by the FDA and has been used to treat over 100,000 men globally. With TFX placing the available market opportunity in the U.S. at $6 billion due to the fact that 1.5 million men with BPH have abandoned treatment, UroLift is expected to continue to fuel significant revenue.Additionally, its new MANTA vascular closure device looks especially promising. With the full launch of MANTA slated for 2020, Jeffries analyst Raj Denhoy believes TFX has a “best-in-class reported and organic top-line growth profile relative to peers”. He added, “With TFX now positioned as one of the better positioned mid-cap hospital supply providers, the company is now increasingly attractive to larger diversified medtech peers."As a result, the five-star analyst reiterated a Buy rating and $415 price target on TFX stock. Based on Denhoy's price target, shares could surge 29% over the next twelve months. (To watch Denhoy’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to TFX. 6 Buy ratings and 1 Hold give the stock a ‘Strong Buy’ analyst consensus. Its $397 average price target suggests 24% upside potential. (See Teleflex stock analysis on TipRanks)DuPont de Nemours (DD)It’s no question that the chemical company has received its fair share of negative attention in recent years. Nonetheless, DuPont shares could get a lift thanks to its focus on active portfolio management.Management believes synergies resulting from recent M&A activity could drive substantial gains in terms of revenue. On October 3, DD announced that it had agreed to acquire the Memcor business from Evoqua Water Technologies Corporation. As a result of the deal, Dupont will get access to Evoqua’s ultrafiltration and membrane biofiltration technologies. This acquisition comes on the heels of an earlier agreement with BASF to acquire the ultrafiltration membrane segment of the business.Not to mention the company should see cash flow improve following the sale of its Compound Semiconductor Solutions business.Bearing this in mind, Morgan Stanley analyst Vincent Andrews sees DD’s potential 12-month gain falling at 28%, as he reiterates an Overweight rating and $85 price target. (To watch Andrews’ track record, click here)“We remain of the view that: 1) A ~$100 per share bull case exists should the company achieve max strategic value creation with its four generally unrelated segments; 2) The current share price does not price in any strategic value creation, but rather a typical conglomerate discount,” Andrews noted.Wall Street anchor a bullish perspective on the chemicals maker, as TipRanks analytics showcase DD as a Moderate Buy. Based on 12 analysts polled by TipRanks in the last 3 months, 8 rate DD a "buy," while 4 say "hold." The 12-month average price target stands at $80.82, marking a nearly 20% upside from where the stock is currently trading. (See DuPont stock analysis on TipRanks)Corteva (CTVA)Originally the agricultural component of DowDuPont, Corteva is now a separate company specializing in agricultural chemicals and seeds. With shares dipping 8% in the last month, Deutsche Bank’s David Begleiter argues that the drop represents a unique buying opportunity.The company has recently added a new bundling program called Corteva Cash, with the product already proving to be successful. The bundling program gives seed purchasers a cash credit that can be used to buy pesticides from Corteva. As a result, there has been an uptick in purchases of CTVA pesticides from farmers.In addition to Corteva Cash, the company has placed a significant focus on improving its productivity levels. CTVA recently announced the launch of its “Execute to Win” productivity program to fuel $500 million of EBITDA over the next five years. A new ERP platform is also being put into place in order to address excess costs from its three disparate IT systems including DuPont Crop Protection, Pioneer and Dow Agrosciences, as well as simplify business operations.All of this lends itself to Begleiter’s conclusion that CTVA’s 2x EBITDA discount to FMC Corporation is “unwarranted”. “With double-digit EBITDA growth over the next 3-4 years largely in its own control (due to its substantial cost synergies and productivity initiatives) and valuation compelling versus its closest peer, we reiterate our Buy rating,” he commented. Along with his Buy rating, the five-star analyst set a $35 price target, indicating 37% upside potential. (To watch Begleiter’s track record, click here)Overall, the agricultural chemical maker has had 3 bullish analysts in its corner over the last three months, along with 2 neutral analysts. Importantly, the 12-month average price target of $33,40 showcases 25% in upside potential for the stock.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 20% in 2019 (through September 30th). Conversely, hedge […]
WILMINGTON, Del., Oct. 16, 2019 /PRNewswire/ -- Corteva Agriscience (NYSE: CTVA) announced today a $500,000 commitment to create the Corteva Agriscience Climate Positive Challenge to catalyze a movement toward climate-positive agriculture. The grant program will be launched next year and reward efforts that offset carbon emissions and protect the environment while sustaining farms and farmers. The challenge grants will provide financial rewards to farmers who are already advancing innovative climate-positive practices for collaborating with local environmental groups, universities, growers or others in the ag value chain to help scale the effort beyond their own acres.
Baird upgraded shares of agricultural seed and chemicals provider FMC to Buy on Wednesday, believing new products will drive profit growth.
WILMINGTON, Del., Oct. 10, 2019 /PRNewswire/ -- Corteva Agriscience (CTVA) today announced that Neal Gutterson, Ph.D., Senior Vice President and Chief Technology Officer (CTO), has indicated his intent to retire from the Company in the second half of 2020. Neal remains fully committed to Corteva and to leading the R&D organization until his successor is selected and for a period after to assure a smooth transition. The Company has engaged an executive recruitment firm to identify a replacement.
A widely used agricultural pesticide that California environmental officials have said has been linked to brain damage in children will be banned after next year under an agreement reached with the manufacturer, state officials announced Wednesday.
WILMINGTON, Del., Oct. 9, 2019 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) today announced its Board of Directors has authorized a common stock dividend of 13 cents per share, payable December 18, 2019, to the Company's shareholders of record on November 29, 2019. This marks the second continuous cash dividend to be paid by Corteva since becoming an independent public company on June 1, 2019. The Board of Directors of E. I. du Pont de Nemours and Company (EID) declared regular preferred stock dividends of $1.12-1/2 per share on the $4.50 series preferred stock and $0.87-1/2 per share on the $3.50 series preferred stock – both payable January 24, 2020 to EID stockholders of record on January 10, 2020.
Every investor in Corteva, Inc. (NYSE:CTVA) should be aware of the most powerful shareholder groups. Insiders often...
Since seed and crop chemical company Corteva CTVA was spun out of DowDuPont in June, we think the market has focused on near-term uncertainties like the effects of flooded U.S. fields and the dry start to the Brazilian planting season. If plantings pick up in October, the effect could be that sales simply shift from Corteva's third quarter to the fourth, similar to the delayed U.S. plantings in 2018. Regardless, we remain optimistic on Corteva's long-term outlook and view the shares as undervalued.